OptimizeRx Corporation (OPRX)
Oxford Ledge is still expanding full research coverage of OPRX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
OptimizeRx provides digital marketing technology connecting pharmaceutical companies with healthcare providers and patients through AI-powered targeting and omnichannel platforms.
SEC filings
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-12
- 8-K Departure/election of directors or officers 2026-06-05
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 8-K Entry into material agreement; Termination of material agreement; Results of operations / financial condition; Creation of direct financial obligation; Financial statements and exhibits 2026-05-12
- DEF 14A Proxy statement for shareholder vote 2026-04-30
Source: SEC EDGAR.
Annual results
5 years of annual figures for OPRX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $109.4M | $5.1M | $0.27 |
| 2024 | $92.1M | -$20.1M | -$1.10 |
| 2023 | $71.5M | -$17.6M | -$1.03 |
| 2022 | $62.5M | -$11.4M | -$0.64 |
| 2021 | $61.3M | $378,079 | $0.02 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for OPRX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open OPRX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.